Hematologic Malignancies Program

恶性血液病计划项目总结 血液恶性疾病计划(HMP)由51名科学家和来自7个国家的临床研究人员组成 在罗切斯特、明尼苏达州(MCR)、亚利桑那州(MCA)和佛罗里达州(MCF)的梅奥诊所的科室。该计划是联合- 由Ansell博士(MCR)、Bergsagel博士(MCA)和Chanan-Khan博士(MCF)领导。HMP的目标是1)调查 恶性血液病的流行病学和进展机制，2)分子和 恶性血液病的细胞生物学，以确定新的治疗靶点，以及3)开发和测试新的 治疗。为了实现这些目标，HMP被组织成4个疾病组(DGs)，这些疾病组由 基础和转化性研究科学家、血液病理学家和临床医生。副总干事每周或 两周一次，讨论研究结果、临床试验活动和使用生物库样本和 确保研究满足我们集水区患者的需求。年度同行直接评审 向HMP成员提供的资金为460万美元，其中93%来自国家癌症研究所。这包括2个孢子 (淋巴瘤和多发性骨髓瘤)，15个R01，2个R41，1个R21，1个U54，5个多发性骨髓瘤研究基金会 和2笔白血病和淋巴瘤协会赠款。自2012年以来，HMP已经招募了10名新科学家 专注于从细胞信号到癌症存活率的关键研究领域。主要科学贡献由 自2012年以来的氟氯烃管理计划包括在批准nivolumab治疗霍奇金淋巴瘤方面发挥重要作用，领导 全基因组关联研究确定大细胞淋巴瘤的易感基因，在 确定ibrutinb在慢性淋巴细胞性白血病中的作用的试验，以及在包括Bortezomib在内的试验中的领先地位 多发性骨髓瘤。HMP继续有一个强大的临床试验计划，招募了500多名患者 每年都要进行临床治疗试验。自成立以来，成员已为文学作品贡献了1172种出版物 2013年，其中43%是方案内的，30%是方案间的。HMP成员拥有广泛的 与成员在基因和病毒治疗、实验治疗和遗传学方面的合作 流行病学和风险评估课程。HMP成员广泛使用大量共享 资源，大量使用生物谱系的加入和加工、生物统计学和药剂学。 机构和慈善机构(Predolin基金会)继续为氟氯烃管理计划相关研究提供重要支持。在……里面 在下一个资助期，我们将指导年轻的研究人员，并专注于开发整合基因组的工具 信息纳入我们患者的个人护理计划中。

HEMATOLOGIC MALIGNANCIES PROGRAM PROJECT SUMMARY The Hematologic Malignancies Program (HMP) is composed of 51 scientists, and clinical investigators from 7 departments at Mayo Clinic in Rochester, MN (MCR), Arizona (MCA), and Florida (MCF). The Program is co- led by Drs. Ansell (MCR), Bergsagel (MCA) and Chanan-Khan (MCF). The HMP aims are to 1) investigate the epidemiology of hematologic malignancies and mechanisms of progression, 2) characterize the molecular and cell biology of hematologic malignancies to identify new therapeutic targets, and 3) develop and test new therapies. To accomplish these aims, the HMP is organized into 4 disease groups (DGs) that are composed of basic and translational research scientists, hematopathologists, and clinicians. The DGs meet weekly or biweekly to discuss research results, clinical trial activities, and requests for use of biobank samples and ensure that research is meeting the needs of the patients in our catchment area. Annual peer-reviewed direct funding to HMP members is $4.6M, with 93% from the National Cancer Institute. This includes 2 SPOREs (Lymphoma and Multiple Myeloma), 15 R01s, 2 R41s, 1 R21, 1 U54, 5 Multiple Myeloma Research Foundation and 2 Leukemia and Lymphoma Society grants. Since 2012, the HMP has recruited 10 new scientists who focus on key research areas ranging from cell signaling to cancer survivorship. Major scientific contributions by the HMP since 2012 include a major role in the approval of nivolumab in Hodgkin lymphoma, leadership in genome wide association studies (GWAS) identifying susceptibility loci in large cell lymphoma, leadership in trials establishing the role of ibrutinb in CLL, and leadership in trials including bortezomib in frontline therapy for multiple myeloma. The HMP continues to have a robust clinical trials program that enrolls over 500 patients each year to therapeutic clinical trials. Members have contributed 1172 publications to the literature since 2013, 43% of which are intraprogrammatic and 30% interprogrammatic. HMP members have extensive collaborations with members in the Gene and Virus Therapy, Experimental Therapeutics, and Genetic Epidemiology and Risk Assessment Programs. HMP members make extensive use of numerous Shared Resources, with substantial use of Biospecimens Accessioning & Processing, Biostatistics, and Pharmacy. Significant institutional and philanthropic (Predolin Foundation) support continues for HMP-related research. In the next funding period, we will mentor young investigators and focus on developing tools to integrate genomic information into the individual care plans for our patients.